OncoMatch/Clinical Trials/NCT07121946
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Is NCT07121946 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including LTZ-301 and LTZ-301 for non-hodgkin lymphoma refractory/ relapsed.
Treatment: LTZ-301 · LTZ-301 · LTZ-301 — This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a single agent in adult subjects with relapsed or refractory B-cell non-Hodgkin lymphoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: allogeneic stem cell transplant
Prior allogeneic stem cell transplant
Cannot have received: autologous stem cell transplant
Exception: within 100 days prior to the first LTZ-301 administration
ASCT within 100 days prior to the first LTZ-301 administration
Cannot have received: CAR-T cell therapy
Exception: within 60 days prior to the first LTZ-301 administration
Prior CAR-T within 60 days prior to the first LTZ-301 administration
Cannot have received: solid organ transplant
Prior solid organ transplant
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Cardiac function
adequate cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- Washington University School of Medicine · St Louis, Missouri
- Roswell Park Cancer Institute · Buffalo, New York
- Tennessee Oncology · Nashville, Tennessee
- Fred Hutchinson Cancer Center · Seattle, Washington
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07121946 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic stem cell transplant, autologous stem cell transplant, CAR-T cell therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify